Project Grant R21CA303396
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$406K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30303, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), is providing $572,254 over a 3-year period starting February 1, 2025 to identify the first selective inhibitors of PLC𝜸1 and PLC𝜸2. The research aims to screen 200,000 compounds to discover small molecule inhibitors of these two phospholipase C gamma enzymes, which have been implicated in driving oncogenesis. The project will employ high-throughput screening...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the Foundation For Applied Molecular Evolution, Inc. provides $215,564 to develop new molecular reagents called "AegisBody" and "AegisCleavers" for cancer research. These novel reagents can bind to and covalently cleave target proteins, like the cancer-relevant PD-L1 protein, unlike traditional antibodies. The goal is to create these more stable and cost-effective...
The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,500.00 to Chapman University to develop and evaluate peptide-doxorubicin conjugates for mitigating cardiotoxicity and overcoming drug resistance in cancer. The key objectives are to investigate the mechanisms by which these peptide-drug conjugates can selectively target and kill drug-resistant cancer cells while reducing adverse cardiotoxic effects, and to conduct in vivo...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $563,233 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Medical University of South Carolina. The 5-year grant, which commenced on April 1, 2025, supports research to investigate how the sphingosine kinase 2 (SPHK2)/sphingosine-1-phosphate (S1P) axis regulates the immunosuppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The key objectives...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
This federal Project Grant award, valued at $849,371.00, was issued on August 2, 2024 by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research aimed at "Hijacking Post-Translational Arginylation for Targeted Protein Degradation" at the Washington University in St. Louis. The key research activities include: Applying computational techniques to identify potential ATE1 binder hits for targeted protein degradation....